Fengying Wu

机构：Tongji University, University of British Columbia, Anhui Medical University, Shantou University, University of Saskatchewan, Fifth Hospital of Shijiazhuang, Nanfang Hospital, Shanghai Pulmonary Hospital, Shanghai Sixth People's Hospital, Second Affiliated Hospital of Anhui Medical University, Wuhan University of Science and Technology, Nanfang College Guangzhou, Chengdu University of Traditional Chinese Medicine · ORCID：0000-0001-5129-0528

发表论文 170 篇 · 总被引 4474 次 · h-index 29

代表论文

• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• Multi-omics with dynamic network biomarker algorithm prefigures organ-specific metastasis of lung adenocarcinoma (2024 · Nature Communications · 被引 21)
• IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC (2025 · Molecular Cancer · 被引 18)
• Research on the LLM-Driven Vulnerability Detection System Using LProtector (2024 · 被引 16)
• Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial (2025 · Signal Transduction and Targeted Therapy · 被引 7)
• GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma (2025 · Journal of Thoracic Oncology · 被引 6)